Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mingfu Zhu and Dinesh Patel


Tute Genomics has hired Mingfu Zhu to serve as its director of bioinformatics and lead research and development efforts in the area.

Prior to joining the company, Zhu was an assistant professor at the Center for Human Genome Variation at Duke University. His research interests at Duke were in computational genomics and statistical genetics. Zhu has bachelors and doctoral degrees in mathematics from the University of Science and Technology of China and Clemson University, respectively. He received postdoctoral training in bioinformatics at Duke University.

Recently, Tute also announced that Dinesh Patel joined its board of directors. Patel is the co-founder of Signal Peak Ventures — formerly called vSpring Capital. He has also held leading roles at several life sciences companies including TheraTech, which was acquired by Actavis — formerly Watson Pharmaceuticals — and Mediconnect, which was acquired by Verisk Analytics.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.